RxDoctor Payments DataLook up a doctor →

Dharmesh Patel, MD

Cardiovascular Disease · Southaven, MSNPI 1689651036

Payments from drug & device makers

$1,929,704in general payments, 2019–2025

Across 2,318 payments — averaging $832.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$472K
  • Novartis$411K
  • Amgen$331K
  • Bayer$145K
  • Novo Nordisk$108K
  • Lilly USA, LLC$103K
  • plus $359K from 48 others
$4,145in research payments, 2019–2025

Across 1 payment — averaging $4144.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson392$471,871
Novartis104$411,091
Amgen416$330,795
Bayer163$145,389
Novo Nordisk65$108,335
Lilly USA, LLC108$103,171
Esperion Therapeutics, Inc.130$75,845
Amarin Pharma, Inc.87$69,623
Boehringer Ingelheim108$68,602
AstraZeneca136$57,606
Medtronic(2 entities)146$41,445
Ionis Pharmaceuticals, Inc.15$10,584
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$5,875
Merck41$4,338
Sanofi-aventis U.S. LLC14$4,318
Janssen Global Services, LLC8$4,100
Amryt Pharma Holdings Ltd19$3,825
Regeneron5$3,608
Arbor Pharmaceuticals, Inc.32$1,338
Chiesi USA, Inc.4$1,107
Abbott53$1,085
Philips North America LLC51$952
Alnylam Pharmaceuticals Inc.32$643
Pfizer36$614
E.r. Squibb & Sons, L.L.C.32$474
Regeneron Healthcare Solutions, Inc.15$459
Irhythm Technologies, Inc.17$399
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)16$314
Boston Scientific8$223
Impulse Dynamics (USA) Inc.4$196
Cleerly, Inc.1$156
Edwards Lifesciences3$153
Cvrx, Inc.5$133
Braemar Manufacturing, LLC1$133
Astellas Pharma US Inc2$117
Azurity Pharmaceuticals, Inc.5$96
Kowa Pharmaceuticals America, Inc.6$94
Heartflow, Inc.5$81
Janssen Scientific Affairs, LLC1$69
Actelion Pharmaceuticals US, Inc.5$67
Bardy Diagnostics, Inc.4$60
Lexicon Pharmaceuticals, Inc.3$54
Lundbeck LLC3$52
Hitachi Healthcare Americas Corp.1$50
Daiichi Sankyo Inc.1$25
Gilead2$22
Sobi, Inc1$22
Cardiovascular Systems Inc.1$17
Eisai Inc.1$17
Medicure Pharma Inc.1$16
Scpharmaceuticals Inc.1$14
Preventice Services, LLC1$13
Biotronik Inc.1$12
G Medical Diagnostic Services, Inc.1$5

How this compares

$1,929,704 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi →

Medicare billing

Part B allowed, 2024
$714,018
Medicare patients
3,237
Services billed
16,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Southaven

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →